Study of Allergic Bronchopulmonary Aspergillosis (ABPA)

N Nassirabady1

Author address: 

1Department of Microbiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran



Allergic Broncho-Pulmonary Aspergillosis is a condition for which there is as yet no complete cure, so it is managed using steroids and antifungals in order to avoid any lung damage.The purpose of this study is related to a pulmonary Aspergillus allergy.


There are eight criteria that have been suggested as indicative of ABPA:Episodic wheezing (asthma),Eosinophilia (increase in the number of certain white blood cells which fight disease),Immediate skin test reactivity to Aspergillus antigens,Precipitating (IgG) antibodies to Aspergillus,Elevated total IgE,Elevated Aspergillus-specific IgE,Central bronchiectasis (widening of the airways),History of pulmonary infiltrates (seen on X-ray) .


Studies showed that Treatment consists of long term use of steroids (e.g. prednisolone) to reduce inflammation and lung damage. There are several potential difficulties with the use of steroid drugs for long periods but their use is vital to prevent the disease progressing.


ABPA is a hypersensitivity reaction to A fumigatus colonization of the tracheobronchial tree and occurs in conjunction with asthma and cystic fibrosis (CF).We can now often reduce the amount of steroids taken by ABPA patients by giving the patient an antifungal medication such as itraconazole (Sporanox). This seems to keep the fungus under control and some people can stop taking steroids completely for periods of time.


abstract No: 


Full conference title: 

5th Advances Against Aspergillosis
    • AAA 5th (2012)